<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO> FR89512-0104 </DOCNO><DOCID>fr.5-12-89.f2.A1103</DOCID><TEXT><ITAG tagnum="69"><ITAG tagnum="52">Importation of Controlled Substances; Application by Sigma ChemicalCo.</ITAG>Pursuant to section 1008 of the Controlled Substances Import and ExportAct (21 U.S.C. 958(h)), the Attorney General shall, prior to issuing aregistration under this section to a bulk manufacturer of a controlledsubstance in Schedule I or II and prior to issuing a regulation under section1002(a) authorizing the importation of such a substance, provide manufacturersholding registrations for the bulk manufacture of the substance an opportunityfor a hearing.  Therefore, in accordance with andSection; 1311.42 of Title 21, Code of FederalRegulations (CFR), notice is hereby given that on February 9, 1989, SigmaChemical Company, 3500 Dekalb Street, St. Louis, Missouri 63118, made applicationto the Drug Enforcement Administration to be registered as an importerof the basic classes of controlled substances listed below: <ITAG tagnum="110"><C>2,L2,tp0,s50,9</C> <H1>Drug:</H1><H1>Schedule</H1> <ITAG tagnum="1">Methaqualone (2565) <D>I </D></ITAG><ITAG tagnum="1">Ibogaine (7260) <D>I </D></ITAG><ITAG tagnum="1">Lysergic acid diethylamide (7315) <D>I </D></ITAG><ITAG tagnum="1">Marihuana (7360) <D>I </D></ITAG><ITAG tagnum="1">Tetrahydrocannabinols (7370) <D>I </D></ITAG><ITAG tagnum="1">Mescaline (7381) <D>I </D></ITAG><ITAG tagnum="1">2,5-dimethoxyamphetamine (7396) <D>I </D></ITAG><ITAG tagnum="1">3,4-methylenedioxyamphetamine (7400) <D>I </D></ITAG><ITAG tagnum="1">3,4-methylenedioxymethamphetamine (MDMA) (7405) <D>I </D></ITAG><ITAG tagnum="1">4-methoxyamphetamine (7411) <D>I </D></ITAG><ITAG tagnum="1">Bufotenine (7433) <D>I </D></ITAG><ITAG tagnum="1">Diethyltryptamine (7434) <D>I </D></ITAG><ITAG tagnum="1">Dimethyltryptamine (7435) <D>I </D></ITAG><ITAG tagnum="1">Psilocybin (7437) <D>I </D></ITAG><ITAG tagnum="1">Psilocyn (7438) <D>I </D></ITAG><ITAG tagnum="1">Etorphine, except Hydrochloride (9056) <D>I </D></ITAG><ITAG tagnum="1">Heroin (9200) <D>I </D></ITAG><ITAG tagnum="1">Beta-Hydroxyfentanyl (9830) <D>I </D></ITAG><ITAG tagnum="1">Amphetamine, its salts, optical isomers, and salts of its optical isomers(1100) <D>II </D></ITAG><ITAG tagnum="1">Methamphetamine, its salts, isomers, and salts of its isomers (1105)<D>II </D></ITAG><ITAG tagnum="1">Secobarbital (2315) <D>II </D></ITAG><ITAG tagnum="1">Phencyclidine (7471) <D>II </D></ITAG><ITAG tagnum="1">Anileridine (9020) <D>II </D></ITAG><ITAG tagnum="1">Cocaine (9041) <D>II </D></ITAG><ITAG tagnum="1">Codeine (9050) <D>II </D></ITAG><ITAG tagnum="1">Diprenorphine (9058) <D>II </D></ITAG><ITAG tagnum="1">Benzoylecgonine (9180) <D>II </D></ITAG><ITAG tagnum="1">Methadone (9250) <D>II </D></ITAG><ITAG tagnum="1">Bulk Dextropropoxyphene (9273) <D>II </D></ITAG><ITAG tagnum="1">Morphine (9300) <D>II </D></ITAG><ITAG tagnum="1">Morphine-3-glucuronide (9329) <D>II </D></ITAG><ITAG tagnum="1">Oxymorphone (9652) <D>II</D></ITAG></ITAG> Any manufacturer holding, or applying for, registration as a bulk manufacturerof this basic class of controlled substance may file written comments onor objections to the application described above and may, at the same time,file a written request for a hearing on such application in accordancewith 21 CFR 1301.54 in such form as prescribed by 21 CFR 1316.47.  Any such comments, objections or requests for a hearing may be addressedto the Deputy Assistant Administrator, Drug Enforcement Administration,United States Department of Justice, 1405 I Street, NW., Washington, DC20537, Attention: DEA Federal Register Representative (Room 1112), andmust be filed no later than (30 days from publication).  This procedure is to be conducted simultaneously with and independent ofthe procedures described in 21 CFR 1311.42 (b), (c), (d), (e) and (f).As noted in a previous notice at 40 FR 43745-46 (September 23, 1975), allapplicants for registration to import a basic class of any controlled substancein Schedule I or II are and will continue to be required to demonstrateto the Deputy Assistant Administrator of the Drug Enforcement Administrationthat the requirements for such registration pursuant to 21 U.S.C. 958(a),21 U.S.C. 823(a), and 21 CFR 1311.42 (a), (b), (c), (d), (e) and (f) aresatisfied. <ITAG tagnum="6">Gene R. Haislip,</ITAG><ITAG tagnum="4">Deputy Assistant Administrator, Office of Diversion Control, Drug EnforcementAdministration.</ITAG><ITAG tagnum="21">Dated: May 2, 1989.</ITAG><ITAG tagnum="40">[FR Doc. 89-11386 Filed 5-11-89; 8:45 am]</ITAG><ITAG tagnum="68">BILLING CODE 4410-09-M</ITAG></ITAG></TEXT></DOC>